Array BioPharma Inc. (NASDAQ:ARRY) reported Q4 2017 earnings this Morning, coming in at ($0.17) per share, beating Wall Street’s estimates of ($0.21) per Share. Revenue for the quarter came in at $33.80 million beating analyst estimates of $28.64 million
Analyst Coverage For Array BioPharma Inc. (NASDAQ:ARRY)
These are 1 Hold Rating, 6 Buy Ratings .
The current consensus rating for Array BioPharma Inc. (NASDAQ:ARRY) is Buy (Score: 2.86) with a consensus target price of $11.86 , a potential (50.09% upside)Recent Insider Trading for Array BioPharma Inc. (NASDAQ:ARRY)
- On 3/28/2017 Charles M Baum, Director, sold 25,000 with an average share price of $9.27 per share and the total transaction amounting to $231,750.00.
- On 9/28/2016 Redmile Group, Llc, Major Shareholder, sold 2,492,578 with an average share price of $6.36 per share and the total transaction amounting to $15,852,796.08.
- On 9/15/2016 Redmile Group, Llc, Major Shareholder, bought 400,000 with an average share price of $3.51 per share and the total transaction amounting to $1,404,000.00.
- On 1/20/2016 Redmile Group, Llc, Major Shareholder, bought 300,000 with an average share price of $3.19 per share and the total transaction amounting to $957,000.00.
- On 1/12/2016 Redmile Group, Llc, Major Shareholder, bought 75,000 with an average share price of $3.60 per share and the total transaction amounting to $270,000.00.
- On 1/11/2016 Redmile Group, Llc, Major Shareholder, bought 925,000 with an average share price of $3.67 per share and the total transaction amounting to $3,394,750.00.
Recent Trading for Array BioPharma Inc. (NASDAQ:ARRY) Shares of Array BioPharma Inc. closed the previous trading session at 8.60 up +0.70 8.86% with 2,599,550 shares trading hands.